<PAGE> 1
===============================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------
FORM 8-K
CURRENT REPORT,
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (Date of Earliest Event Reported): June 18, 1997 (June 13, 1997)
NU-TECH BIO-MED, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware 0-11772 25-1411971
- ---------------------------- ------------------------ -------------------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation Identification No.)
55 Access Road
Warwick, Rhode Island 02886
--------------------- -----
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (401) 732-6520
-----------------
===============================================================================
<PAGE> 2
ITEM 5. OTHER EVENTS.
On April 29, 1997, Nu-Tech Bio-Med, Inc. (the "Company") reduced the
exercise price of 1,076,979 warrants (the "Warrants") and 15,856 options (the
"Options"), respectively, to $1.76 per share, which price is equal to 75% of
the average closing price for the Company's common stock for the ten (10) days
prior to such reduction. Such reduction was effected for a 45 day period
through June 13, 1997. As of June 13, 1997, the Company received an aggregate
of approximately $619,000 as a result of the exercise of 351,728 options/
warrants.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report on Form 8-K to be signed on its
behalf by the undersigned hereunto duly authorized.
NU-TECH BIO-MED, INC.
By: /s/ J. Marvin Feigenbaum
-------------------------------
Name: J. Marvin Feigenbaum
Title: Chairman of the Board, President, Chief
Executive and Chief Financial Officer
Date: June 18, 1997
2
